BiotechTube

Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solution

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioequivalence

Conditions

Bioequivalence, Healthy Volunteers

Trial Timeline

Jul 3, 2017 → Jul 17, 2017

NCT ID
NCT03213353

About Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solution

Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solution is a phase 1 stage product being developed by Johnson & Johnson for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT03213353. Target conditions include Bioequivalence, Healthy Volunteers.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03213353Phase 1Completed

Competing Products

20 competing products in Bioequivalence

See all competitors
ProductCompanyStageHype Score
Bupropion HCl MR tablets 300mgAlembic PharmaceuticalsPhase 1
32
Fingolimod 0.5 mg capsules- Test drugAlembic PharmaceuticalsPhase 1
32
Lamotrigine ER tablet 50mgAlembic PharmaceuticalsPhase 1
32
Sonelokimab + SonelokimabMoonLake ImmunotherapeuticsPhase 1
28
GP30101 + Prezista® + GP30101 + Prezista®GEROPHARMPre-clinical
15
Metformin + Glucophage® + Metformin + Glucophage®GEROPHARMPhase 1
25
Metformine + Glucophage® Long + Metformin + Glucophage® LongGEROPHARMPhase 1
25
Humulin® Regular + Rinsulin® RGEROPHARMPre-clinical
15
Bosentan 125 mg + Tracleer 125Mg TabletGEROPHARMPhase 1
25
Rinsulin® mix 30/70 + Humulin® M3GEROPHARMPre-clinical
15
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mgGEROPHARMPhase 1
25
Clocortolone PivalateSun PharmaceuticalPhase 1
33
Oxymetazoline hydrochloride Cream, 1% + Rhofade™ (oxymetazoline) cream, 1% + PlaceboSun PharmaceuticalPhase 1
33
SHR-1314Jiangsu Hengrui MedicinePhase 1
33
Onglyza (saxagliptin) + Diabex + 5-mg saxagliptin/1000 mg metformin + Diabex + 5-mg saxagliptin/500 mg metforminAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
OmeprazoleAstraZenecaPhase 1
33
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)AstraZenecaPhase 1
33
D961S + Esomeprazole + Buffered acetylsalicylic acidAstraZenecaPhase 1
33
Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsuleAstraZenecaPhase 1
33

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85